Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML)

Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment optio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hofmann, Susanne (VerfasserIn) , Schubert, Maria-Luisa (VerfasserIn) , Wang, Lei (VerfasserIn) , He, Bailin (VerfasserIn) , Neuber, Brigitte (VerfasserIn) , Dreger, Peter (VerfasserIn) , Müller-Tidow, Carsten (VerfasserIn) , Schmitt, Michael (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 6 February 2019
In: Journal of Clinical Medicine
Year: 2019, Jahrgang: 8, Heft: 2, Pages: 1-14
ISSN:2077-0383
DOI:10.3390/jcm8020200
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/jcm8020200
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2077-0383/8/2/200
Volltext
Verfasserangaben:Susanne Hofmann, Maria-Luisa Schubert, Lei Wang, Bailin He, Brigitte Neuber, Peter Dreger, Carsten Mueller-Tidow and Michael Schmitt
Beschreibung
Zusammenfassung:Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment option in intermediate and high risk AML. It is the proof-of-concept for T cell-based immunotherapies in AML based on the graft-versus-leukemia (GvL)-effect, but it also bears the risk of graft-versus-host disease. CD19-targeting therapies employing chimeric antigen receptor (CAR) T cells are a breakthrough in cancer therapy. A similar approach for myeloid malignancies is highly desirable. This article gives an overview on the state-of-the art of preclinical and clinical studies on suitable target antigens for CAR T cell therapy in AML patients.
Beschreibung:Gesehen am 26.11.2024
Beschreibung:Online Resource
ISSN:2077-0383
DOI:10.3390/jcm8020200